Mozavaptan: Difference between revisions

Revision as of 13:11, 24 November 2011 editBeetstra (talk \| contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEMBL').← Previous edit		Revision as of 13:22, 24 November 2011 edit undoCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or [[user talk:CheMoBot\|bug...Next edit →
Line 1:		Line 1:
	{{Drugbox		{{Drugbox
			\| Verifiedfields = changed
	\| verifiedrevid = 455185272		\| verifiedrevid = 455185272
	\| IUPAC_name = ''N''--2-methylbenzamide		\| IUPAC_name = ''N''--2-methylbenzamide
Line 24:		Line 25:

	<!--Identifiers-->		<!--Identifiers-->
			\| CAS_number_Ref = {{cascite\|correct\|??}}
	\| CAS_number = 137975-06-5		\| CAS_number = 137975-06-5
	\| ATC_prefix = none		\| ATC_prefix = none
Line 32:		Line 34:
	\| StdInChIKey_Ref = {{stdinchicite\|correct\|chemspider}}		\| StdInChIKey_Ref = {{stdinchicite\|correct\|chemspider}}
	\| StdInChIKey = WRNXUQJJCIZICJ-UHFFFAOYSA-N		\| StdInChIKey = WRNXUQJJCIZICJ-UHFFFAOYSA-N
			\| ChEMBL_Ref = {{ebicite\|changed\|EBI}}
	\| ChEMBL = 420762		\| ChEMBL = 420762
	\| PubChem = 119369		\| PubChem = 119369

Revision as of 13:22, 24 November 2011

Pharmaceutical compound

Mozavaptan
Clinical data

Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name N--2-methylbenzamide
CAS Number	137975-06-5
PubChem CID	119369
ChemSpider	106618
UNII	17OJ42922Y
ChEMBL	ChEMBL420762
CompTox Dashboard (EPA)	DTXSID8057641
Chemical and physical data
Formula	C₂₇H₂₉N₃O₂
Molar mass	427.53 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
InChI InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N
(what is this?) (verify)

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

H. Spreitzer (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
Prous Science: Molecule of the Month November 2006

CA inhibitors (at PT)	Acetazolamide
Loop (Na-K-Cl at AL)	Furosemide Azosemide Bumetanide Etacrynic acid Etozolin Indacrinone Muzolimine Ozolinone Piretanide Tienilic acid Torasemide
Thiazides (Na-Cl at DCT, Calcium-sparing)	Altizide Bendroflumethiazide Butizide Chlorothiazide Cyclopenthiazide Cyclothiazide Epitizide Hydrochlorothiazide Hydroflumethiazide Mebutizide Methyclothiazide Polythiazide Trichlormethiazide
Thiazide-likes (primarily DCT)	Chlortalidone Clofenamide Clopamide Clorexolone Fenquizone Indapamide Mefruside Meticrane Metolazone Quinethazone Xipamide

Other

Combination products

This antihypertensive-related article is a stub. You can help Misplaced Pages by expanding it.